CJC-1295
CJC-1295 (DAC:GRF; Growth Hormone Releasing Factor (1-29) analog with Drug Affinity Complex)
Not FDA-approved. Not on the FDA Category 1 or Category 2 compounding lists. Available as a research chemical only.
A lab-made peptide that triggers the pituitary gland (a small gland in the brain that controls hormone production) to release growth hormone over several days from a single injection. It is not FDA-approved and has only been studied in small research trials.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Most adverse effects are mild and transient. No dose-limiting toxicities reported in Phase I trials up to 60 mcg/kg. One death (myocardial infarction) occurred in Phase II trial but was adjudicated as unrelated to CJC-1295 (patient had pre-existing coronary artery disease). No evidence of tolerance or tachyphylaxis in studies up to 7 weeks. Long-term safety data (>3 months) in humans are not available. Immunogenicity (antibody formation) is a concern, especially with compounded products (impurities, aggregates); this was a specific concern noted by FDA PCAC. No consistent withdrawal syndrome documented.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-5]